R-CHOP protocol

11/01/2015 - "Deliverability and efficacy of R-CHOP chemotherapy in very elderly patients with diffuse large B-cell lymphoma: an Australian retrospective analysis."
01/01/2020 - "Outcomes for patients with high-risk diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP chemotherapy are suboptimal but, to date, no alternative regimen has been shown to improve survival rates. "
06/01/2009 - "To our knowledge, this is the second report to date of a patient with primary bilateral adrenal diffuse large B-cell lymphoma who achieved complete remission using R-CHOP chemotherapy."
12/17/2014 - "This study was a substudy of a parent study designed to compare a 3-week with a 2-week R-CHOP chemotherapy regimen for untreated diffuse large B-cell lymphoma. "
01/01/2023 - "R-CHOP chemotherapy has been established as the first-line standard treatment for elderly patients diagnosed with diffuse large B-cell lymphoma. "

05/22/2013 - "Multifocal primary bone lymphoma: durable complete remission after R-CHOP chemotherapy."
05/01/2002 - "The association of the antibody to CHOP (R-CHOP) chemotherapy increases in diffuse large cells lymphomas by approximately 15% complete remission rate (63% vs 76%) and survival. "
07/01/2010 - "[A case of primary hepato-biliary malignant lymphoma effectively treated with R-CHOP chemotherapy]."
01/01/2019 - "Although the patient responded to R-CHOP chemotherapy, he developed central nervous system involvement by lymphoma. "
12/01/2017 - "Here we report the successful treatment of lymphoma-associated PNP and BO using R-CHOP chemotherapy. "

03/01/2019 - "The suggested diagnosis was a malignant retroperitoneal tumor and the patient underwent an excision of the tumor throw a lombotomy followed by an R-CHOP chemotherapy regimen with good outcome."
07/01/2021 - "Treatment with R-CHOP chemotherapy was initiated, with complete tumor regression by the third cycle. "
12/01/2018 - "Following two cycles of R-CHOP chemotherapy, imaging showed significant decrease in size of the sellar tumor. "
10/01/2016 - "The aim of this study was to analyze the prognostic value of the interim PET (iPET)-computed tomography (CT) (iPET-CT) after two cycles of immunochemotherapy with the R-CHOP protocol in patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL) treated with a curative intent in combination with the neoplastic cell origin defined by Hans's immunohistochemstry algorithm followed in a reference center for cancer treatment in Brazil. "
01/01/2016 - "To classify cancer samples validly, eight significant genes (MYBL1, LMO2, BCL6, MME, IRF4, NFKBIZ, PDE4B, and SLA) were selected in 414 patients treated with CHOP/R-CHOP chemotherapy from Gene Expression Omnibus (GEO) data sets. "

11/01/2016 - "Full uncapped doses of R-CHOP chemotherapy administered to obese patients with non-Hodgkin lymphoma (NHL) are safe, well tolerated, and do not lead to inferior treatment response or long-term outcomes."
07/01/2015 - "Effect of R-CHOP chemotherapy on liver and mediastinal blood pool (18)F-FDG standardized uptake values in patients with non-Hodgkin's lymphoma."
02/01/2015 - "[Supportive care for patients with non-Hodgkin lymphoma receiving R-CHOP chemotherapy]."
02/01/2015 - "Reduced-dose (two-thirds) R-CHOP chemotherapy for elderly patients with non-Hodgkin lymphoma."
11/01/2011 - "Neurological syndrome after R-CHOP chemotherapy for a non-Hodgkin lymphoma: what is the diagnosis?"

03/01/2012 - "Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma."
01/01/2016 - "This study aims to compare the cost-effectiveness of various strategies of myeloid growth factor prophylaxis for reducing the risk of febrile neutropenia (FN) in patients with non-Hodgkin lymphoma in Singapore who are undergoing R-CHOP chemotherapy with curative intent. "
10/01/2022 - "Predictive Parameters of Febrile Neutropenia and Clinical Significance of G-CSF Receptor Signaling Pathway in the Development of Neutropenia during R-CHOP Chemotherapy with Prophylactic Pegfilgrastim in Patients with Diffuse Large B-Cell Lymphoma."
01/01/2016 - "Routine Primary Prophylaxis for Febrile Neutropenia with Biosimilar Granulocyte Colony-Stimulating Factor (Nivestim) or Pegfilgrastim Is Cost Effective in Non-Hodgkin Lymphoma Patients undergoing Curative-Intent R-CHOP Chemotherapy."
11/01/2017 - "The incidence of and risk factors for febrile neutropenia (FN) in Japanese non-Hodgkin B-cell lymphoma (B-NHL) patients receiving rituximab, cyclophosphamide, doxorubicin, vincristine, and predonisolone (R-CHOP) chemotherapy are unknown. "